Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis

被引:0
|
作者
Katie Forbes
Karin Gillette
Laura A. Kelley
Inder Sehgal
机构
[1] North Dakota State University,Center for Protease Research
[2] North Dakota State University,USDA Laboratory
[3] Louisiana State University,School of Veterinary Medicine, Comparative Biomedical Sciences
来源
World Journal of Urology | 2004年 / 22卷
关键词
Urokinase plasminogen activator receptor; Prostate cancer; Secondary metastasis; Motility;
D O I
暂无
中图分类号
学科分类号
摘要
To understand alterations to the urokinase system that may occur in progressively metastatic prostate cancer cells, we assessed urokinase plasminogen activator receptor (uPAR) expression, in vitro motility towards vitronectin, urokinase plasminogen activator (uPA)-induced growth and growth factor regulation of uPAR expression in three cell lines—PC-3 and two derivatives from secondary metastases, PC-3M and PC-3MM2. DU-145 and Tsu-Pr1 cells were included for comparative purposes. uPAR expression increases with metastatic passage in these cell lines and accompanies increased growth and motility responses in the presence of uPA. Growth factors TGFβ1 and IGF-1 induce uPAR in all three prostate cancer lines; however, PC-3M and PC-3MM2 cells also respond to bFGF. Of the cell lines tested, PC-3MM2 most uniformly respond to added TGFβ1, IGF-1 and bFGF. These results show that in two progressive derivatives from repeated metastasis of PC-3 cells, constitutive and growth factor-induced uPAR expression is enhanced. This increased uPAR facilitates the properties of growth and motility.
引用
收藏
页码:67 / 71
页数:4
相关论文
共 50 条
  • [21] Targeting of urokinase-type plasminogen activator receptor in oral cancer cells inhibits invasion and metastasis in vivo
    Nozaki, Shinichi
    Endo, Yoshio
    Nakahara, Hirokazu
    Yoshizawa, Kunio
    Hashiba, Yukari
    Kawashiri, Shuichi
    Tanaka, Akira
    Nakagawa, Kiyomasa
    Yamamoto, Etsuhide
    CANCER RESEARCH, 2006, 66 (08)
  • [22] The urokinase plasminogen activator system in breast cancer invasion and metastasis
    Tang, Linlin
    Han, Xiuzhen
    BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (02) : 179 - 182
  • [23] Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer
    Cozzi, Paul J.
    Wang, Jian
    Delprado, Warick
    Madigan, Michele C.
    Fairy, Stephen
    Russell, Pamela J.
    Li, Yong
    HUMAN PATHOLOGY, 2006, 37 (11) : 1442 - 1451
  • [24] Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade
    Evans, CP
    Elfman, F
    Parangi, S
    Conn, M
    Cunha, G
    Shuman, MA
    CANCER RESEARCH, 1997, 57 (16) : 3594 - 3599
  • [25] Increased vascular endothelial growth factor in tumor cells and increased production of the receptor for urokinase plasminogen activator in endothelial cells are associated with lymph node metastasis in human breast cancer
    Bastholm, L
    Nielsen, MH
    Enggaard, C
    Rank, F
    Elling, F
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 1999, 7 (01): : 39 - 47
  • [26] Urokinase plasminogen activator receptor levels in Behcet's disease
    Birengel, Serhat
    Yalcindag, F. Nilufer
    Yalcindag, Ali
    Sahli, Esra
    Batioglu, Figen
    THROMBOSIS RESEARCH, 2011, 128 (03) : 274 - 276
  • [27] Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma
    Li, P
    Gao, Y
    Ji, ZZ
    Zhang, XS
    Xu, Q
    Li, GC
    Guo, ZT
    Zheng, BJ
    Guo, XK
    JOURNAL OF PEDIATRIC SURGERY, 2004, 39 (10) : 1512 - 1519
  • [28] Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor
    Nozaki, S
    Endo, Y
    Nakahara, H
    Yoshizawa, K
    Hashiba, Y
    Kawashiri, S
    Tanaka, A
    Nakagawa, K
    Matsuoka, Y
    Kogo, M
    Yamamoto, E
    ORAL ONCOLOGY, 2005, 41 (10) : 971 - 977
  • [29] Inhibition of urokinase plasminogen activator expression by deferoxamine in cultured human prostate cancer cells
    Ornstein, DL
    Zacharki, LR
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2263 - P2263
  • [30] Identification of urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) as therapeutic targets for pancreatic cancer.
    Della Croce, K
    Han, H
    Beroza, P
    Bearss, DJ
    von Hoff, DD
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3668S - 3668S